ACG Wealth bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,308 shares of the medical research company’s stock, valued at approximately $252,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Edwards Lifesciences Corporation by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock valued at $2,453,311,000 after purchasing an additional 406,901 shares during the period. BlackRock Inc. boosted its stake in Edwards Lifesciences Corporation by 0.8% in the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after purchasing an additional 105,819 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences Corporation by 161.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after purchasing an additional 3,277,726 shares in the last quarter. American Century Companies Inc. lifted its stake in Edwards Lifesciences Corporation by 7.0% during the 3rd quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock valued at $243,107,000 after acquiring an additional 144,701 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in Edwards Lifesciences Corporation by 13.3% during the 2nd quarter. Wells Fargo & Company MN now owns 2,119,260 shares of the medical research company’s stock valued at $250,581,000 after acquiring an additional 248,293 shares during the period. Hedge funds and other institutional investors own 82.17% of the company’s stock.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $112.45, for a total transaction of $3,699,605.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $112.58, for a total value of $2,134,516.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 158,540 shares of company stock valued at $17,130,243. 2.13% of the stock is owned by company insiders.

Several research firms recently issued reports on EW. Deutsche Bank AG decreased their target price on shares of Edwards Lifesciences Corporation from $122.00 to $115.00 and set a “hold” rating for the company in a research note on Thursday, October 26th. Morgan Stanley cut their price target on shares of Edwards Lifesciences Corporation from $133.00 to $120.00 and set an “overweight” rating for the company in a report on Thursday, October 26th. Barclays PLC cut their price target on shares of Edwards Lifesciences Corporation from $120.00 to $118.00 and set an “equal weight” rating for the company in a report on Wednesday, October 25th. SunTrust Banks, Inc. set a $124.00 target price on shares of Edwards Lifesciences Corporation and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $135.00 target price (down previously from $155.00) on shares of Edwards Lifesciences Corporation in a report on Wednesday, October 25th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Edwards Lifesciences Corporation has a consensus rating of “Buy” and a consensus target price of $125.17.

Shares of Edwards Lifesciences Corporation (EW) traded up $2.12 during midday trading on Friday, hitting $107.10. The stock had a trading volume of 954,400 shares, compared to its average volume of 1,638,442. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.45. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The company has a market cap of $22,590.00, a P/E ratio of 29.08, a price-to-earnings-growth ratio of 1.88 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. Edwards Lifesciences Corporation’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.68 earnings per share. research analysts forecast that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/acg-wealth-takes-position-in-edwards-lifesciences-corporation-ew/1709641.html.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.